{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:30:22Z","timestamp":1789882222196,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T00:00:00Z","timestamp":1444953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10072-015-2395-7","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T09:56:47Z","timestamp":1444989407000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline"],"prefix":"10.1007","volume":"37","author":[{"given":"Luca","family":"Degli Esposti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Sangiorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,16]]},"reference":[{"key":"2395_CR1","unstructured":"Prevalence of Parkinson\u2019s Disease (2014) http:\/\/www.epda.eu.com\/en\/resources\/life-with-parkinsons\/part-1\/prevalence-of-parkinsons-disease\/ . Accessed 19 Nov 2014"},{"issue":"6","key":"2395_CR2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM Lau de","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535","journal-title":"Lancet Neurol"},{"issue":"3","key":"2395_CR3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.30.3.250","volume":"30","author":"G Rosati","year":"1980","unstructured":"Rosati G, Granieri E, Pinna L, Aiello I, Tola R, De BP, Pirisi A, Devoto MC (1980) The risk of Parkinson disease in Mediterranean people. Neurology 30(3):250\u2013255","journal-title":"Neurology"},{"key":"2395_CR4","doi-asserted-by":"crossref","unstructured":"Morgante L, Rocca WA, Di Rosa AE, De DP, Grigoletto F, Meneghini F, Reggio A, Savettieri G, Castiglione MG, Patti F (1992) Prevalence of Parkinson\u2019s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian neuro-epidemiologic study (SNES) group. Neurology 42(10):1901\u20131907","DOI":"10.1212\/WNL.42.10.1901"},{"issue":"1","key":"2395_CR5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0404.2005.00426.x","volume":"112","author":"R Totaro","year":"2005","unstructured":"Totaro R, Marini C, Pistoia F, Sacco S, Russo T, Carolei A (2005) Prevalence of Parkinson\u2019s disease in the L\u2019Aquila district, central Italy. Acta Neurol Scand 112(1):24\u201328","journal-title":"Acta Neurol Scand"},{"key":"2395_CR6","unstructured":"NICE guidelines [CG35]:Parkinson\u2019s disease: diagnosis and management in primary and secondary care (2006) https:\/\/www.nice.org.uk\/guidance\/cg35 . Accessed 19 Nov 2014"},{"issue":"16","key":"2395_CR7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311(16):1670\u20131683","journal-title":"JAMA"},{"key":"2395_CR8","unstructured":"Approved Drug Products Eldepryl (1996) http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails . Accessed 19 Nov 2014"},{"key":"2395_CR9","unstructured":"European public assessment report (EPAR)\u2014Azilect (2005) http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000574\/human_med_000667.jsp&mid=WC0b01ac058001d124 . Accessed 19 Nov 2014"},{"key":"2395_CR10","unstructured":"Approved Drug Products Azilect (2006) http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails . Accessed 19 Nov 2014"},{"issue":"10","key":"2395_CR11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) DATATOP: a multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol 46(10):1052\u20131060","journal-title":"Arch Neurol"},{"issue":"12","key":"2395_CR12","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59(12):1937\u20131943","journal-title":"Arch Neurol"},{"issue":"9463","key":"2395_CR13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947\u2013954","journal-title":"Lancet"},{"issue":"2","key":"2395_CR14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248","journal-title":"Arch Neurol"},{"issue":"15","key":"2395_CR15","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","volume":"23","author":"CW Olanow","year":"2008","unstructured":"Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson\u2019s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23(15):2194\u20132201","journal-title":"Mov Disord"},{"issue":"1","key":"2395_CR16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4140\/TCP.n.2011.48","volume":"26","author":"DS Knudsen Gerber","year":"2011","unstructured":"Knudsen Gerber DS (2011) Selegiline and rasagiline: twins or distant cousins? Consult Pharm 26(1):48\u201351","journal-title":"Consult Pharm"},{"issue":"4","key":"2395_CR17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.23517","volume":"26","author":"R Stowe","year":"2011","unstructured":"Stowe R, Ives N, Clarke CE, Handley K, Furmston A, Deane K, van Hilten JJ, Wheatley K, Gray R (2011) Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson\u2019s disease. Mov Disord 26(4):587\u2013598","journal-title":"Mov Disord"},{"issue":"13","key":"2395_CR18","first-page":"1879","volume":"18","author":"S Marconi","year":"2014","unstructured":"Marconi S, Zwingers T (2014) Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 18(13):1879\u20131882","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2395_CR19","unstructured":"Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson\u2019s disease (2012) http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0054173\/ . Accessed 19 Nov 2014"},{"key":"2395_CR20","unstructured":"The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) ATC\/DDD Index 2014 (2014) http:\/\/www.whocc.no\/atc_ddd_index\/ . Accessed 19 Nov 2014"},{"key":"2395_CR21","unstructured":"Banca Dati del Farmaco e del Parafarmaco (2014) http:\/\/www.farmadati.it\/ . Accessed 19 Nov 2014"},{"issue":"6","key":"2395_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000302644","volume":"7","author":"Y Winter","year":"2010","unstructured":"Winter Y, von Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Boetzel K, Eggert K, Oertel WH, Dodel R, Barone P (2010) Costs of Parkinson\u2019s disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis 7(6):365\u2013372","journal-title":"Neurodegener Dis"},{"issue":"1\u20132","key":"2395_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2010.04.011","volume":"294","author":"Y Winter","year":"2010","unstructured":"Winter Y, Balzer-Geldsetzer M, von Campenhausen S, Spottke A, Eggert K, Oertel WH, Dodel R (2010) Trends in resource utilization for Parkinson\u2019s disease in Germany. J Neurol Sci 294(1\u20132):18\u201322","journal-title":"J Neurol Sci"},{"issue":"2","key":"2395_CR24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3111\/13696998.2012.737392","volume":"16","author":"F Valldeoriola","year":"2013","unstructured":"Valldeoriola F, Puig-Junoy J, Puig-Peiro R (2013) Cost analysis of the treatments for patients with advanced Parkinson\u2019s disease: SCOPE study. J Med Econ 16(2):191\u2013201","journal-title":"J Med Econ"},{"issue":"4","key":"2395_CR25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1345\/aph.1G454","volume":"40","author":"J Hudry","year":"2006","unstructured":"Hudry J, Rinne JO, Keranen T, Eckert L, Cochran JM (2006) Cost-utility model of rasagiline in the treatment of advanced Parkinson\u2019s disease in Finland. Ann Pharmacother 40(4):651\u2013657","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2395_CR26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/aje\/kwr081","volume":"174","author":"F Moisan","year":"2011","unstructured":"Moisan F, Gourlet V, Mazurie JL, Dupupet JL, Houssinot J, Goldberg M, Imbernon E, Tzourio C, Elbaz A (2011) Prediction model of Parkinson\u2019s disease based on antiparkinsonian drug claims. Am J Epidemiol 174(3):354\u2013363","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2395_CR27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"2395_CR28","unstructured":"International Classification of Diseases 9th Revision Clinical Modification\u2014ICD9-CM (2009) http:\/\/icd9cm.chrisendres.com\/index.php . Accessed 19 Nov 2014"},{"key":"2395_CR29","unstructured":"Norwegian Prescription Database (2014) http:\/\/www.norpd.no\/default.aspx . Accessed 19 Nov 2014"},{"issue":"1","key":"2395_CR30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3111\/13696998.2010.551164","volume":"14","author":"LJ Findley","year":"2011","unstructured":"Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M (2011) The economic burden of advanced Parkinson\u2019s disease: an analysis of a UK patient dataset. J Med Econ 14(1):130\u2013139","journal-title":"J Med Econ"},{"issue":"7","key":"2395_CR31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1517\/14656566.2012.677435","volume":"13","author":"JP Reese","year":"2012","unstructured":"Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R (2012) Pharmacoeconomic considerations of treating patients with advanced Parkinson\u2019s disease. Expert Opin Pharmacother 13(7):939\u2013958","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20132","key":"2395_CR32","first-page":"24","volume":"319","author":"DC Suh","year":"2012","unstructured":"Suh DC, Pahwa R, Mallya U (2012) Treatment patterns and associated costs with Parkinson\u2019s disease levodopa induced dyskinesia. J Neurol Sci 319(1\u20132):24\u201331","journal-title":"J Neurol Sci"},{"issue":"7 Suppl","key":"2395_CR33","first-page":"S168","volume":"18","author":"DF Boland","year":"2012","unstructured":"Boland DF, Stacy M (2012) The economic and quality of life burden associated with Parkinson\u2019s disease: a focus on symptoms. Am J Manag Care 18(7 Suppl):S168\u2013S175","journal-title":"Am J Manag Care"},{"issue":"3","key":"2395_CR34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","volume":"28","author":"SL Kowal","year":"2013","unstructured":"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson\u2019s disease in the United States. Mov Disord 28(3):311\u2013318","journal-title":"Mov Disord"}],"updated-by":[{"DOI":"10.1007\/s10072-016-2511-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,2,20]],"date-time":"2016-02-20T00:00:00Z","timestamp":1455926400000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2395-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-015-2395-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-015-2395-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:19:15Z","timestamp":1559121555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-015-2395-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,16]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2395"],"URL":"https:\/\/doi.org\/10.1007\/s10072-015-2395-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10072-016-2511-3","asserted-by":"object"}]},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,16]]}}}